Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) EBIT: ¥-114 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301126 Hunan Dajiaweikang Pharmaceutical Industry Co Ltd SZSE:301126
68 GF Score
Price ¥9.00
GF Value ¥12.31
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is Hunan Dajiaweikang Pharmaceutical Industry Co EBIT?

Hunan Dajiaweikang Pharmaceutical Industry Co SZSE:301126 +3.57% 68 EBIT is ¥-114 Mil as of Mar. 2026. GuruFocus rates SZSE:301126 with a GF Score™ of 68/100 and a GF Value™ of ¥12.31 (Modestly Undervalued). The stock has 11 warning signs investors should review.

Hunan Dajiaweikang Pharmaceutical Industry Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥42 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-114 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hunan Dajiaweikang Pharmaceutical Industry Co's annualized ROC % for the quarter that ended in Mar. 2026 was 2.82%. Hunan Dajiaweikang Pharmaceutical Industry Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.55%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hunan Dajiaweikang Pharmaceutical Industry Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2.27%.

Hunan Dajiaweikang Pharmaceutical Industry Co  (SZSE:301126) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hunan Dajiaweikang Pharmaceutical Industry Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=168.068 * ( 1 - 10.58% )/( (5369.354 + 5306.415)/ 2 )
=150.2864056/5337.8845
=2.82 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6336.943 - 992.26 - ( 596.553 - max(0, 3996.108 - 3971.437+596.553))
=5369.354

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6392.702 - 1041.043 - ( 529.867 - max(0, 4032.304 - 4077.548+529.867))
=5306.415

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Hunan Dajiaweikang Pharmaceutical Industry Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=168.068/( ( (961.939 + max(2067.326, 0)) + (952.898 + max(2073.178, 0)) )/ 2 )
=168.068/( ( 3029.265 + 3026.076 )/ 2 )
=168.068/3027.6705
=5.55 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1947.795 + 932.632 + 233.507) - (992.26 + 0 + 54.348)
=2067.326

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2019.478 + 923.009 + 228.475) - (1041.043 + 0 + 56.741)
=2073.178

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hunan Dajiaweikang Pharmaceutical Industry Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-114.179/5029.481
=-2.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hunan Dajiaweikang Pharmaceutical Industry Co EBIT Related Terms

Hunan Dajiaweikang Pharmaceutical Industry Co EBIT Historical Data

* Premium members only.

The historical data trend for Hunan Dajiaweikang Pharmaceutical Industry Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hunan Dajiaweikang Pharmaceutical Industry Co EBIT Chart

Hunan Dajiaweikang Pharmaceutical Industry Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 129.49 113.62 111.66 174.60 -113.67

Hunan Dajiaweikang Pharmaceutical Industry Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.53 20.20 43.97 -220.37 42.02

Hunan Dajiaweikang Pharmaceutical Industry Co EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Hunan Dajiaweikang Pharmaceutical Industry Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hunan Dajiaweikang Pharmaceutical Industry Co EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Hunan Dajiaweikang Pharmaceutical Industry Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hunan Dajiaweikang Pharmaceutical Industry Co's EV-to-EBIT falls into.


SZSE:301126
68GF Score
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd SZSE:301126
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hunan Dajiaweikang Pharmaceutical Industry Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-114 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥-114 Mil mean?
Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) has a EBIT of ¥-114 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hunan Dajiaweikang Pharmaceutical Industry Co.
Is Hunan Dajiaweikang Pharmaceutical Industry Co's EBIT too high?
Hunan Dajiaweikang Pharmaceutical Industry Co's current EBIT is ¥-114 Mil. Overall, Hunan Dajiaweikang Pharmaceutical Industry Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Dajiaweikang Pharmaceutical Industry Co's EBIT compare to competitors?
Hunan Dajiaweikang Pharmaceutical Industry Co's EBIT of ¥-114 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hunan Dajiaweikang Pharmaceutical Industry Co. Hunan Dajiaweikang Pharmaceutical Industry Co's current EBIT is ¥-114 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Dajiaweikang Pharmaceutical Industry Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥12.31, compared to a current price of ¥9.00 — trading 26.9% below its estimated fair value. The current EBIT is ¥-114 Mil. Hunan Dajiaweikang Pharmaceutical Industry Co's overall GF Score™ is 68/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126), the current EBIT is ¥-114 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) Overvalued in 2026?

Based on GuruFocus' analysis, Hunan Dajiaweikang Pharmaceutical Industry Co stock appears to be undervalued. The current stock price of ¥9.00 is trading 26.9% below its estimated GF Value™ of ¥12.31. GuruFocus considers Hunan Dajiaweikang Pharmaceutical Industry Co to be Modestly Undervalued.

Key valuation signals for SZSE:301126:

  • EBIT: ¥-114 Mil
  • GF Value™: ¥12.31 vs. price of ¥9.00 (26.9% below fair value)
  • GF Score™: 68/100 with 11 warning signs

No single metric tells the full story. See the SZSE:301126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hunan Dajiaweikang Pharmaceutical Industry Co Business Description

Address No. 30 Fuling Road, Yuelu District, Hunan Province, Changsha, CHN, 410000
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is engaged in the distribution and retail of pharmaceuticals, biological products, medical equipment and other products.
68GF Score

Get the complete analysis for SZSE:301126

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.00
Price
¥12.31
GF Value